治疗白癜风费用高吗 http://baidianfeng.39.net/bdfby/yqyy/SCI
18February
PembrolizumabPlusIpilimumaborPlaceboforMetastaticNon–Small-CellLungCancerWithPD-L1TumorProportionScore?50%:Randomized,Double-BlindPhaseIIIKEYNOTE-Study(JCO,IF:32.)
BoyerMichael,?endurMehmetAN,Rodríguez-AbreuDelvysetal.PembrolizumabPlusIpilimumaborPlaceboforMetastaticNon-Small-CellLungCancerWithPD-L1TumorProportionScore≥50%:Randomized,Double-BlindPhaseIIIKEYNOTE-Study.[J].JClinOncol,,undefined:JCO.
PURPOSE目的
Pembrolizumabmonotherapyisstandardfirst-linetherapyformetastaticnon-small-celllungcancer(NSCLC)withprogrammeddeathligand1(PD-L1)tumorproportionscore(TPS)≥50%withoutactionabledrivermutations.Itisnotknownwhetheraddingipilimumabtopembrolizumabimprovesefficacyoverpembrolizumabaloneinthispopulation.
帕博利珠单抗是治疗程序性死亡配体1(PD-L1)肿瘤比例评分≥50%且无有效驱动基因突变的转移性非小细胞肺癌的标准一线治疗方案。目前尚不清楚在这一人群中添加伊匹单抗是否比单独使用帕博利珠更有效。
METHODS方法
Intherandomized,double-blind,phaseIIIKEYNOTE-trial(ClinicalTrials.govidentifier:NCT),eligiblepatientswithpreviouslyuntreatedmetastaticNSCLCwithPD-L1TPS≥50%andnosensitizingoraberrationswererandomlyallocated1:1toipilimumab1mg/kgorplaceboevery6weeksforupto18doses;allparticipantsreceivedpembrolizumabmgevery3weeksforupto35doses.Primaryendpointswereoverallsurvivalandprogression-freesurvival.
在随机、双盲、III期Keynote-试验(ClinicalTrials.gov标识符：NCT)中，符合条件的PD-L1TPS≥为50%且无敏感或突变的转移性非小细胞肺癌患者被随机分配为1：1，每6周1mg/kg或安慰剂，最多18次；所有参与者每3周服用帕博利珠单抗mg，最多35次。主要终点是总存活率和无进展存活率。
RESULTS结果
Oftheparticipants,wererandomlyallocatedtoeachgroup.Medianoverallsurvivalwas21.4monthsforpembrolizumab-ipilimumabversus21.9monthsforpembrolizumab-placebo(hazardratio,1.08;95%CI,0.85to1.37;=.74).Medianprogression-freesurvivalwas8.2monthsforpembrolizumab-ipilimumabversus8.4monthsforpembrolizumab-placebo(hazardratio,1.06;95%CI,0.86to1.30;=.72).Grade3-5adverseeventsoccurredin62.4%ofpembrolizumab-ipilimumabrecipientsversus50.2%ofpembrolizumab-placeborecipientsandledtodeathin13.1%versus7.5%.Theexternaldataandsafetymonitoring
